Get Connected:

 

Latest News

First Darunavir-Based Single-Tablet Treatment Regimen for HIV Wins FDA Approval
Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg) is the first and only complete darunavir-based single tablet regimen (STR) for the treatment of HIV-1 in treatment-naïve and certain virologically suppressed adults.
Top news of the day from across the health care landscape.
 
Top news of the day from across the health care landscape.
 
The phase 3 CAPSTONE-2 study of the safety and efficacy of baloxavir marboxil in patients at high risk of complications due to influenza (flu) has met the primary objective of efficacy of a single dose of baloxavir marboxil compared to placebo.
The FDA is alerting health care professionals and patients of a voluntary recall of several, but not all, drug products containing the active ingredient valsartan.
The discovery may pave the way for the development of personalized medicine in order to target this newly discovered form of the disease.
Top news of the day from across the health care landscape.
 
Although eradicated in 1980 due to vaccination efforts, there have been concerns of the virus being used as a potential weapon in bioterrorism. 
View More >

From the Journals

New proposed rules for the Medicare Part D drug program could affect the manner in which pharmacy benefit managers administer the program and could impact profitability.
Healthcare stakeholders must evaluate how to use resources more efficiently as it has become clear that driving down prices in one segment of care has not improved medical outcomes for the majority of patients.
This cost analysis demonstrated that onabotulinumtoxinA is one of the least-costly treatment options for inadequately managed overactive bladder syndrome.
An estimation and comparison of the cost of home phototherapy versus biologics over a 3-year time horizon in patients with moderate-to-severe plaque psoriasis.
The study found no mean difference in all-cause healthcare costs for patients with newly diagnosed nonvalvular atrial fibrillation initiating treatment with dabigatran versus warfarin.
Buprenorphine treatment with and without induction was found to decrease costs and utilization in opioid-dependent benefciaries.
Focusing on cost alone could diminish the vital service aspects behind successfully caring for a patient in a specialty pharmacy.
Upcoming Partner Events